This article is a correction to:
Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
Shuqi Xie
Mengchao Wang
Chuanxiu Zeng
Lu Zhao
Dong Wang
Liwei Chen
Fanming Kong- Department of Oncology, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
A Corrigendum on
Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
By Xie S, Wang M, Zeng C, Ou Y, Zhao L, Wang D, Chen L, Kong F and Yi D (2023) Front. Oncol. 13:1197698. doi: 10.3389/fonc.2023.1197698
Text Correction
In the published article, there was an error in section 3.1.5 Pembrolizumab in combination with lenvatinib regimen
This sentence previously stated: “A multicenter, double-blind, randomized phase III LEAP-012 study showed no significant improvement in the efficacy of systemic combination TACE in combination with lenvatinib + pembrolizumab compared to TACE alone in patients with intermediate-stage HCC.”
The corrected sentence appears below:
“A multicenter, double-blind, randomized phase III LEAP-012 study is underway, which evaluates the efficacy of systemic combination TACE in combination with lenvatinib + pembrolizumab compared to TACE alone in patients with intermediate-stage HCC.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: targeted therapy, immunotherapy, research progress, hepatocellular carcinoma, combination therapy
Citation: Xie S, Wang M, Zeng C, Ou Y, Zhao L, Wang D, Chen L, Kong F and Yi D (2023) Corrigendum: Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma. Front. Oncol. 13:1338060. doi: 10.3389/fonc.2023.1338060
Received: 14 November 2023; Accepted: 23 November 2023;
Published: 13 December 2023.
Edited and Reviewed by:
Zong Sheng Guo, University at Buffalo, United StatesCopyright © 2023 Xie, Wang, Zeng, Ou, Zhao, Wang, Chen, Kong and Yi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Liwei Chen, aXJvbjk5OTlAMTYzLmNvbQ==
†These authors have contributed equally to this work and share first authorship